Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailLow dietary intake calcium in European postmenopausal osteoporotic women
Bruyère, Olivier ULg; DeCock, Caroline; Mottet, Catherine et al

in Public Health Nutrition (2009), 12(1), 111-114

Objective The WHO recommends a daily Ca intake for postmenopausal women of 1300 mg. The objective of the present study was to assess the dietary Ca intake in European postmenopausal osteoporotic women ... [more ▼]

Objective The WHO recommends a daily Ca intake for postmenopausal women of 1300 mg. The objective of the present study was to assess the dietary Ca intake in European postmenopausal osteoporotic women. Design, setting and subjects Assessment of dietary Ca intake (food and supplements) was performed with a validated self-questionnaire in 8524 osteoporotic women from nine European countries (Belgium, Denmark, France, Germany, Hungary, Italy, Poland, Spain and the UK). Results Mean age of the patients was 74·2 (sd 7·1) years, mean BMI was 25·7 (sd 4·2) kg/m2. Of the study population, 37·2 % of the women took Ca supplements. The mean dietary intake of Ca was 930·7 (sd 422·9) mg/d. The lowest Ca intake was found in Hungary (586·7 (sd 319·1) mg/d) and the highest in Denmark (1145·6 (sd 463·0) mg/d). In the whole study population, only 19·1 % of the women had a dietary Ca intake >1300 mg/d. Only 17·1 % of women aged over 75 years achieved 1300 mg/d compared with 20·5 % of women aged less than 75 years (P = 0·0001 for the difference between the two groups). Conclusion Dietary intake of Ca is very low in European postmenopausal women. A greater awareness is needed to resolve this public health problem. [less ▲]

Detailed reference viewed: 77 (29 ULg)
Peer Reviewed
See detailLow dose of dopamine infusion : hemodynamic and natriuretic responses
D'Orio, Vincenzo ULg; El-Allaf, D

in Clinical Pharmacology & Therapeutics (1984), 35

Detailed reference viewed: 1 (0 ULg)
Peer Reviewed
See detailLow doses of FSH stimulate follicular growth and maturation in anestrous heifers.
Beckers, Jean-François ULg; Ballman-Wouters, P; Viviers-Donnay, I et al

in Theriogenology (1989)

Detailed reference viewed: 8 (0 ULg)
Full Text
See detailLow flow regionalisation in the Walloon Region
Grandry, Maud ULg; Verstraete, Arnaud; Gailliez, Sébastien et al

Report (2012)

Detailed reference viewed: 52 (7 ULg)
Full Text
Peer Reviewed
See detailLow frequency electromagnetic waves in periodic structures
Guenneau, S.; Nicolet, A.; Geuzaine, Christophe ULg et al

in International Journal of Applied Electromagnetics and Mechanics (2004), 19

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailLow frequency rythms in human DNA sequences: A key to the organization of gene location and orientation?
Nicolay, Samuel ULg; Argoul, F.; Touchon, M. et al

in Physical Review Letters (2004), 93(10), 108101

We explore large-scale nucleotide compositional fluctuations of the human genome using multi- resolution techniques. Analysis of the GC content and of the AT and GC skews reveals the existence of rhythms ... [more ▼]

We explore large-scale nucleotide compositional fluctuations of the human genome using multi- resolution techniques. Analysis of the GC content and of the AT and GC skews reveals the existence of rhythms with two main periods of 110 20 kb and 400 50 kb that enlighten a remarkable cooperative gene organization. We show that the observed nonlinear oscillations are likely to display all the characteristic features of chaotic strange attractors which suggests a very attractive deterministic picture: gene orientation and location, in relation with the structure and dynamics of chromatin, might be governed by a low-dimensional nonlinear dynamical system. [less ▲]

Detailed reference viewed: 20 (4 ULg)
Peer Reviewed
See detailLow GH hypophyseal adenomas with acromegaly exhibit undetectable levels of messenger RNA of normal GH
Pagesy, P.; Rentier-Delrue, Françoise ULg; Bresson, D. et al

in Annals of Endocrinology (1987), 48

Detailed reference viewed: 17 (0 ULg)
Full Text
Peer Reviewed
See detailLow incidence of anti-osteoporosis treatment after hip fracture.
Rabenda, Véronique ULg; Vanoverloop, Johan; Fabri, Valerie et al

in Journal of Bone & Joint Surgery. American Volume (2008), 90(10), 2142-8

BACKGROUND: Following hip fracture, pharmacologic treatment can reduce the rate of subsequent fragility fractures. The objective of the present study was to assess the proportion of patients who are ... [more ▼]

BACKGROUND: Following hip fracture, pharmacologic treatment can reduce the rate of subsequent fragility fractures. The objective of the present study was to assess the proportion of patients who are managed with bisphosphonates or selective estrogen-receptor modulators after hip fracture and to evaluate, among those managed with alendronate, the twelve-month compliance and persistence with treatment. METHODS: Data were gathered from health insurance companies and were collected by AIM (Agence Intermutualiste) for the Belgian National Social Security Institute (INAMI). We selected all postmenopausal women who had been hospitalized for a hip fracture between April 2001 and June 2004 and had not been previously managed with bisphosphonates. Patients who had received alendronate treatment after the hip fracture were categorized according to their formulation use during the follow-up study (daily, weekly, daily followed by weekly, or weekly followed by weekly). Compliance at twelve months was quantified with use of the medication possession ratio (i.e., the number of days of alendronate supplied during the first year of treatment, divided by 365). Persistence with prescribed treatment was calculated as the number of days from the initial prescription to a lapse of more than five weeks after completion of the previous prescription refill. The cumulative treatment persistence rate was determined with use of Kaplan-Meier survival curves. RESULTS: A total of 23,146 patients who had sustained a hip fracture were identified. Of these patients, 6% received treatment during the study period: 4.6% received alendronate, 0.7% received risedronate, and 0.7% received raloxifene. Bisphosphonate treatment was dispensed to 2.6% and 3.6% of the patients within six months and one year after the occurrence of the hip fracture, respectively. Among women who received alendronate daily (n = 124) or weekly (n = 182) and were followed for at least one year after the hip fracture, the twelve-month mean medication possession ratio was 67% (65.9% in the daily group and 67.7% in the weekly group). The analysis of persistence with treatment included a total of 726 patients (142 in the daily group, 261 in the weekly group, and 323 in the switch group). At twelve months, the rate of persistence was 41% and the median duration of persistence was 40.3 weeks. CONCLUSIONS: The vast majority of patients who experience a hip fracture do not take anti-osteoporotic therapy after the fracture. Furthermore, among patients who begin alendronate treatment after the fracture, the adherence to treatment decreases over time and remains suboptimal. [less ▲]

Detailed reference viewed: 39 (6 ULg)
Full Text
Peer Reviewed
See detailLow incidence of osteoporosis treatment after hip fracture
Rabenda, Véronique ULg; Mertens, Raf; Fabri, Valérie et al

in Osteoporosis International (2007, March), 18(Suppl.1), 72-73

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailLow molecular weight poly (2-dimethylamino ethylmethacrylate) polymers with controlled positioned fluorescent labeling: Synthesis, characterization and in vitro interaction with human endothelial cells.
Flebus, Luca ULg; Lombart, François ULg; Sevrin, Chantal et al

in International journal of pharmaceutics (2015), 478(1), 278-287

Poly (2-dimethylamino ethylmethacrylate) (PDMAEMA) is an attractive non-degradable polymer studied as nonviral vector for gene delivery but it can be also adopted for delivery of other biopharmaceutical ... [more ▼]

Poly (2-dimethylamino ethylmethacrylate) (PDMAEMA) is an attractive non-degradable polymer studied as nonviral vector for gene delivery but it can be also adopted for delivery of other biopharmaceutical drugs. As a parenteral carrier, the PDMAEMA free form (FF) might interact with tissues and cells. Few data are available on its selective internalization and efflux from cells, while the majority of studies published have followed the distribution of DNA complexed with PDMAEMA. In order to address polycation safety, the first aim was to synthesize by atom transfer radical polymerisation (ATRP) fluorescent labeled PDMAEMA of low molecular weight (Mw) (below 15kDa), controlling the position and density of fluorescein. The second goal was to analyze the possible difference in uptake and subcellular distribution of this labeled FF polycation between human umbilical vein endothelial cells (HUVEC) and hCMEC/D3 cells. These two cell lines have been chosen in order to detect selectivity towards the blood-brain barrier (BBB). In both cases, polycation was detected along the plasma membrane followed by progressive migration to the peri-nuclear region, where it overlapped with lysosomal structures. The analysis by fluorescence-activated cell sorting (FACS) of the PDMAEMA uptake by hCMEC/D3 cells showed a significant (p<0.05) inhibition (40%) in presence of 2-dexoxy-d-glucose inhibitor, a result supporting an energy-dependence mechanism(s). Cytotoxicity study showed that low Mw PDMAEMA (10kDa) lead to a minor cytotoxicity compared to the higher ones. As main conclusion this study highlights the similitude in cell trafficking of FF PDMAEMA and data previously reported for PDMAEMA/DNA complexes. [less ▲]

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailA low rate of trisomy 21 in twin-pregnancies: A cytogenetics retrospective study of 278 cases
Jamar, Mauricette ULg; Lemarchal, C.; Koulischer, Lucien ULg et al

in Genetic Counseling (2003), 14(4), 395-400

Detailed reference viewed: 27 (4 ULg)
Full Text
Peer Reviewed
See detailLow risk in fractures in long-term treatment of Paget’s disease with tiludronate
Audran, M; Combe, B; Michaut, S et al

in Journal of Bone and Mineral Research (1996), 11(S1), 372

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailLow sodium diet in essential hypertension- Effect on blood cell ions and hemodynamic parameters
Krzesinski, Jean-Marie ULg; Du, Fenghe; Pequeux, Marie-Louise et al

in American Journal of Hypertension : Journal of the American Society of Hypertension (1992), 5

The influence of salt restriction for 3 months on blood pressure, peripheral vascular resistance (observed by occlusive plethysmography), erythrocyte sodium, platelet calcium, and pH, was studied in eight ... [more ▼]

The influence of salt restriction for 3 months on blood pressure, peripheral vascular resistance (observed by occlusive plethysmography), erythrocyte sodium, platelet calcium, and pH, was studied in eight untreated essential hypertensive patients. A low salt diet decreases blood pressure, vascular resistances, erythrocyte sodium, and platelet calcium, but not platelet pH. A strong positive correlation was noted between baseline platelet calcium and vascular resistances (r=0.95, P < .01). But during the salt restriction period, a negative correlation has been observed between the changes in these parameters, which casts doubt on the use of the platelet as a mode of the smooth muscle cell. [less ▲]

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailLow T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC.
Baron, Frédéric ULg; Baudoux, Etienne ULg; Frere, Pascale ULg et al

in Bone Marrow Transplantation (2003), 32(8), 829-34

We investigate the feasibility of CD34-selected peripheral blood stem cell (PBSC) transplantation followed by pre-emptive CD8-depleted donor lymphocyte infusions (DLI) after a minimal conditioning regimen ... [more ▼]

We investigate the feasibility of CD34-selected peripheral blood stem cell (PBSC) transplantation followed by pre-emptive CD8-depleted donor lymphocyte infusions (DLI) after a minimal conditioning regimen. Six patients with advanced hematological malignancies ineligible for a conventional myeloablative transplant (n=5) or metastatic renal cell carcinoma (n=1), and with an HLA-identical (n=4) or alternative (n=2) donor were included. The nonmyeloablative conditioning regimen consisted in 2 Gy TBI alone (n=4), 2 Gy TBI and fludarabine (RCC patient, n=1) or cyclophosphamide and fludarabine (patient who had previously received 12 Gy TBI, n=1). Post transplant immunosuppression was carried out with cyclosporin (CyA) and mycophenolate mofetil (MMF). Initial engraftment was achieved in all patients. One out of six patients (17%) experienced grade > or =2 acute GVHD only after abrupt cyclosporin discontinuation and alpha interferon therapy for life-threatening tumor progression. T-cell chimerism was 23% (19-30) on day 28, 32% (10-35) on day 100, 78% (49-95) on day 180 and 99.5% (99-100) on day 365. Three out of four patients who had measurable disease before the transplant experienced a complete response. We conclude that CD34-selected NMSCT followed by CD8-depleted DLI is feasible and preserves engraftment and apparently also the graft-versus-leukemia (GVL) effect. Further studies are needed to confirm this encouraging preliminary report. [less ▲]

Detailed reference viewed: 53 (6 ULg)